Piper Jaffray Upgrades Pacific Biosciences of California (PACB) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Pacific Bio (PACB) Q3 Revenue Misses Estimates
October 22, 2015 5:12 PM EDTPacific Bio (NASDAQ: PACB) reported Q3 EPS of $0.02, may not compare to the analyst estimate of ($0.27). Revenue for the quarter came in at $13.9 million versus the consensus estimate of $15.84 million.
For earnings history and earnings-related data on Pacific Bio (PACB) click here.
... More